BR0115833A - Derivados condensados de purina como antagonistas de receptores de adenosina a1 - Google Patents

Derivados condensados de purina como antagonistas de receptores de adenosina a1

Info

Publication number
BR0115833A
BR0115833A BR0115833-3A BR0115833A BR0115833A BR 0115833 A BR0115833 A BR 0115833A BR 0115833 A BR0115833 A BR 0115833A BR 0115833 A BR0115833 A BR 0115833A
Authority
BR
Brazil
Prior art keywords
purine
adenosine
receptor antagonists
condensate derivatives
compounds
Prior art date
Application number
BR0115833-3A
Other languages
English (en)
Inventor
Ko-Chung Lin
Chi Vu
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR0115833A publication Critical patent/BR0115833A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

"DERIVADOS CONDENSADOS DE PURINA COMO ANTAGONISTAS DE RECEPTORES DE ADENOSINA A~ 1~". A presente invenção refere-se a compostos de Fórmulas I e II como antagonistas de receptores de adenosina subtipo A~ 1~. Esses compostos são úteis para tratamento de várias doenças e distúrbios, incluindo hipertensão sistêmica, insuficiência renal, diabetes, asma, uma condição edematosa, insuficiência cardíaca congestiva e disfunção renal.
BR0115833-3A 2000-12-01 2001-11-30 Derivados condensados de purina como antagonistas de receptores de adenosina a1 BR0115833A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25065800P 2000-12-01 2000-12-01
PCT/US2001/044991 WO2002044182A1 (en) 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
BR0115833A true BR0115833A (pt) 2003-10-28

Family

ID=22948640

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115833-3A BR0115833A (pt) 2000-12-01 2001-11-30 Derivados condensados de purina como antagonistas de receptores de adenosina a1

Country Status (33)

Country Link
US (2) US6605601B2 (pt)
EP (1) EP1347981B1 (pt)
JP (2) JP2004514723A (pt)
KR (1) KR20040011439A (pt)
CN (1) CN100497340C (pt)
AR (1) AR035400A1 (pt)
AT (1) ATE394402T1 (pt)
AU (2) AU2002219977B2 (pt)
BG (1) BG107849A (pt)
BR (1) BR0115833A (pt)
CA (1) CA2430508C (pt)
CZ (1) CZ20031513A3 (pt)
DE (1) DE60133931D1 (pt)
EA (1) EA009814B1 (pt)
EE (1) EE200300260A (pt)
ES (1) ES2305139T3 (pt)
GE (1) GEP20094697B (pt)
HK (1) HK1059927A1 (pt)
HU (1) HUP0400530A3 (pt)
IL (1) IL156046A0 (pt)
IS (1) IS6821A (pt)
MX (1) MXPA03004857A (pt)
MY (1) MY127120A (pt)
NO (1) NO20032483L (pt)
NZ (1) NZ526511A (pt)
PL (1) PL362642A1 (pt)
SK (1) SK6552003A3 (pt)
TR (1) TR200300766T2 (pt)
TW (1) TWI293301B (pt)
UA (1) UA75625C2 (pt)
WO (1) WO2002044182A1 (pt)
YU (1) YU42903A (pt)
ZA (2) ZA200304067B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047931A1 (fr) * 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Derives de purine fondue
UA75625C2 (en) * 2000-12-01 2006-05-15 Biogen Inc Condensed purine derivatives as a1 adenosine receptor antagonists
EP1601649A4 (en) * 2003-02-19 2009-03-04 Endacea Inc A1-adenosine receptor antagonistic
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
KR20060005376A (ko) * 2003-04-25 2006-01-17 교와 핫꼬 고교 가부시끼가이샤 축합 피리미딘 유도체
KR20060004959A (ko) 2003-04-25 2006-01-16 노바카르디아, 인코포레이션 신장 기능 저하를 갖는 개별 대상자의 이뇨 작용 개선 방법
JP4859666B2 (ja) * 2003-06-06 2012-01-25 エンダセア， インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
CA2601032A1 (en) * 2005-03-11 2006-09-21 Aderis Pharmaceuticals, Inc. Substituted 9-alkyladenines and the use thereof
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
CN101420958A (zh) * 2006-04-06 2009-04-29 挪瓦卡尔迪阿公司 共投与腺苷a1受体拮抗剂和抗惊厥药
MX2008014672A (es) 2006-05-19 2009-03-09 Abbott Lab Derivados de alcano azabiciclico sustituidos con bicicloheterociclo fusionado activos en el sistema nervioso central.
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
AR061626A1 (es) 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
BRPI0713619A2 (pt) 2006-06-23 2013-01-15 Incyte Corp composto ou prà-droga ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço, e, uso do composto.
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
WO2011063268A2 (en) * 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
AU2019205661B2 (en) * 2018-01-04 2022-06-30 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
EP0423805B1 (en) * 1989-10-20 2000-08-23 Kyowa Hakko Kogyo Kabushiki Kaisha Condensed purine derivatives
DK0605637T3 (da) 1991-09-23 1999-10-11 Univ Florida State Fremstilling af substituerede isoserinestere under anvendelse af metalalkoxider og beta-lactamer
AU4471297A (en) * 1996-10-07 1998-05-05 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
AU740770B2 (en) * 1997-06-18 2001-11-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
US6489331B1 (en) * 1998-07-02 2002-12-03 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
WO2001047931A1 (fr) * 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Derives de purine fondue
UA75625C2 (en) * 2000-12-01 2006-05-15 Biogen Inc Condensed purine derivatives as a1 adenosine receptor antagonists

Also Published As

Publication number Publication date
CN1481387A (zh) 2004-03-10
US20020111333A1 (en) 2002-08-15
JP2010053148A (ja) 2010-03-11
BG107849A (bg) 2004-01-30
MY127120A (en) 2006-11-30
KR20040011439A (ko) 2004-02-05
EP1347981A1 (en) 2003-10-01
EE200300260A (et) 2003-08-15
ZA200304067B (en) 2005-05-30
JP2004514723A (ja) 2004-05-20
HUP0400530A2 (hu) 2004-06-28
US7022686B2 (en) 2006-04-04
WO2002044182A1 (en) 2002-06-06
CA2430508C (en) 2010-05-18
US20030220358A1 (en) 2003-11-27
AR035400A1 (es) 2004-05-26
GEP20094697B (en) 2009-06-10
NO20032483L (no) 2003-07-30
ES2305139T3 (es) 2008-11-01
YU42903A (sh) 2006-05-25
ATE394402T1 (de) 2008-05-15
EA200300629A1 (ru) 2003-12-25
EP1347981B1 (en) 2008-05-07
CZ20031513A3 (cs) 2003-09-17
AU2002219977B2 (en) 2008-01-24
MXPA03004857A (es) 2003-08-19
IS6821A (is) 2003-05-20
TWI293301B (en) 2008-02-11
CN100497340C (zh) 2009-06-10
US6605601B2 (en) 2003-08-12
IL156046A0 (en) 2003-12-23
SK6552003A3 (en) 2003-12-02
PL362642A1 (en) 2004-11-02
HUP0400530A3 (en) 2007-05-29
TR200300766T2 (tr) 2004-09-21
UA75625C2 (en) 2006-05-15
AU1997702A (en) 2002-06-11
DE60133931D1 (de) 2008-06-19
NO20032483D0 (no) 2003-06-02
NZ526511A (en) 2005-04-29
ZA200408755B (en) 2005-07-27
EA009814B1 (ru) 2008-04-28
HK1059927A1 (en) 2004-07-23
CA2430508A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
BR0115833A (pt) Derivados condensados de purina como antagonistas de receptores de adenosina a1
DK1444233T3 (da) A2B-adenosinreceptorantagonister
PT1054887E (pt) Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y
EA200200560A1 (ru) Полициклоалкилпурины в качестве антагонистов аденозиновых рецепторов
MX2009005358A (es) Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
ES2062403T3 (es) 5-((tetrazolil)-alquenil)-imidazoles sustituidos.
DE69034103D1 (de) Imidazoalkensäure
EA200200921A1 (ru) Полуамиды малоновой кислоты и их производные в качестве лигандов тиреоидных рецепторов
BRPI0510762A (pt) derivados de tetraidronaftiridina úteis como ligantes do receptor de histamina h3
ATE242254T1 (de) Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung
WO2002044142A3 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders
BR0007864A (pt) Composto, e, uso de um composto
ATE418555T1 (de) A2a-adenosinrezeptorantagonisten
EA200800264A1 (ru) Производные пиразоло[3,4-d]азепина как антагонисты н3-рецепторов гистамина
TR199900486T2 (xx) Aziniloksi ve fenoksi-diaril-karbonasit t�revleri.
ATE119524T1 (de) Substituierte n-(imidazolyl)alkyl-alanin- derivate.
CO5460266A1 (es) Novedosos analogos de la somatostatina
EA200200562A1 (ru) Антагонисты аденозиновых рецепторов и способы их получения и использования
BR0214582A (pt) Derivados de piperazina para uso como antagonista do receptor ccr-3 no tratamento de asma
WO2006114666A8 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
EA200500830A1 (ru) Производные имидазохинолина в качестве лигандов аденозиновых a3 рецепторов
DE60327375D1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
NO20002655L (no) 5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som <alfa>-adrenoceptoragonister med forbedret metabolisk stabilitet
DZ3119A1 (fr) Nouveaux dérivés de n-triazolylmethyl-piperazines comme antagonistes des recepteurs de la neurokinine.
ATE227276T1 (de) Neue pyrimidinderivate

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOGEN IDEC MA, INC. (US)

Free format text: ALTERADO DE: BIOGEN, INC.

B25D Requested change of name of applicant approved

Owner name: BIOGEN IDEC MA INC. (US)

Free format text: ALTERADO DE: BIOGEN IDEC MA, INC.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements